List of Excipients in Branded Drug RUBY-FILL

RUBY-FILL Excipient Strategy and Commercial Opportunities in Rubidium-82 PET Imaging

Last updated: September 29, 2026

RUBY-FILL is a strontium-82/rubidium-82 generator used to produce rubidium Rb-82 chloride injection for positron emission tomography myocardial perfusion imaging. Its commercial value is driven by generator availability, isotope supply, radiopharmacy workflow, and PET utilization rather than by a conventional drug formulation. The principal excipient strategy is a sterile 0.9% sodium chloride carrier with no preservative-dependent formulation platform. Commercial opportunities therefore concentrate on generator systems, isotope production, sterile fluid pathways, quality-control products, and automated cardiac PET infrastructure.

What is RUBY-FILL and how is it used?

RUBY-FILL is a radiopharmaceutical generator approved by the U.S. Food and Drug Administration for producing rubidium Rb-82 chloride injection. The product is used in adults undergoing PET myocardial perfusion imaging at rest or during pharmacologic stress [1].

The generator contains strontium-82, which decays to rubidium-82. A saline eluent passes through the generator and collects the radioactive rubidium-82 chloride for intravenous administration. Rubidium-82 has a physical half-life of approximately 75 seconds, allowing rapid imaging but requiring on-site or near-site production and immediate administration.

Product attribute	RUBY-FILL profile
Product type	Strontium-82/rubidium-82 generator
Active imaging agent	Rubidium-82 chloride
Primary use	PET myocardial perfusion imaging
Eluent	Sterile 0.9% sodium chloride injection
Rubidium-82 half-life	Approximately 75 seconds
Parent isotope	Strontium-82
Administration	Intravenous
Primary manufacturer	Jubilant DraxImage Inc., part of Jubilant Radiopharma
FDA pathway	New drug application for a radiopharmaceutical generator
Conventional generic model	Not applicable in the same manner as tablets or injectables

The short half-life prevents practical off-site distribution of a finished rubidium-82 dose. This creates a generator-centered business model in which the generator, sterile fluid circuit, dose calibrator, infusion system, and PET scanner operate as one commercial workflow.

What excipients are used in RUBY-FILL?

The principal formulation vehicle is sterile 0.9% sodium chloride injection. FDA labeling describes the generated product as rubidium Rb-82 chloride injection in sodium chloride injection [1].

The formulation does not rely on a complex excipient system. Public labeling does not identify a preservative, surfactant, antioxidant, viscosity modifier, or specialty stabilizer as a functional component of the administered dose. The limited excipient profile reflects the physical properties of the product:

• Rubidium-82 decays within minutes.
• The dose is produced immediately before administration.
• The final solution is administered intravenously.
• The product must remain compatible with the generator column and sterile fluid pathway.
• Residual parent isotope and other radionuclide impurities must remain controlled.
• The solution must support rapid, reproducible elution rather than long-term shelf stability.

For conventional pharmaceutical companies, this limits opportunities to create differentiated RUBY-FILL formulations through excipient substitution. A formulation containing phosphate, citrate, chelators, antioxidants, or antimicrobial preservatives could create compatibility, extractables, sterility, radiochemical purity, or regulatory issues without improving the clinical product.

How does the RUBY-FILL excipient strategy affect commercialization?

The excipient strategy shifts value away from formulation IP and toward system integration. The commercial product is the generator and its validated operating environment, not simply the saline-based injection.

Key commercial requirements include:

1. Sterile saline supply that meets the generator’s validated specifications.
2. Low-sorption, low-extractables tubing and disposable fluid paths.
3. Reliable automated elution and dose measurement.
4. Radiation shielding and safe waste handling.
5. Rapid quality-control testing.
6. Integration with PET scheduling and pharmacologic stress protocols.
7. Supply-chain control for strontium-82.

A supplier that sells saline alone would face limited differentiation. A supplier offering a validated sterile fluid set, closed transfer circuit, dose calibrator interface, and automated quality-control package could capture more value.

What formulations are protected by the RUBY-FILL product design?

RUBY-FILL’s product design protects a generator-based production method more than a conventional finished-dose formulation. The technical protection points are likely to center on:

• Parent-daughter radionuclide generation.
• Adsorption and elution of strontium-82 and rubidium-82.
• Generator-column materials and geometry.
• Control of strontium breakthrough.
• Radionuclide purity.
• Sterile fluid routing.
• Dose measurement and automated delivery.
• Generator replacement and end-of-life controls.

The saline carrier is commercially necessary but technically undifferentiated. Its value comes from validated use with the generator. An alternative excipient or carrier would need to demonstrate equivalent elution performance, sterility, chemical compatibility, radionuclide purity, patient safety, and dose accuracy.

What is the FDA regulatory status of RUBY-FILL?

RUBY-FILL was approved by FDA for rubidium Rb-82 chloride generation for PET myocardial perfusion imaging. The approved use is limited to adult patients and requires administration under the labeled generator and imaging conditions [1].

Radiopharmaceutical regulation combines several controls:

• FDA approval of the drug or generator.
• Manufacturing controls for the radionuclide generator.
• Sterility and particulate controls.
• Radionuclide identity and purity testing.
• Strontium breakthrough limits.
• Radioactive-material licensing.
• State or federal radiation-safety requirements.
• Site-specific radiopharmacy procedures.

The product is not interchangeable with a conventional injectable containing a stable salt. The short half-life and generator operation create a distinct regulatory and operational category.

What is the Orange Book status of RUBY-FILL?

RUBY-FILL is not commercially exposed to generic substitution in the same way as a small-molecule tablet or standard injectable. A competitor would need to supply a comparable strontium-82/rubidium-82 generator, obtain FDA approval, establish radionuclide and sterility controls, and meet radiation-safety requirements.

The relevant competitive pathway is therefore a competing approved generator rather than a routine abbreviated new drug application based solely on chemical equivalence. Any Orange Book patent listing, exclusivity designation, or reference-product status must be evaluated against the current FDA database and the applicable NDA record. The FDA label itself does not establish a conventional formulation patent barrier [1].

When does RUBY-FILL lose exclusivity?

RUBY-FILL does not have a simple tablet-style loss-of-exclusivity date that automatically produces generic entry. Market entry depends on several independent barriers:

Barrier	Commercial effect
FDA regulatory approval	Requires approval of a competing generator or radiopharmaceutical
Strontium-82 supply	Limits manufacturing scale and continuity
Generator performance	Requires control of elution, breakthrough, and radionuclide purity
Short rubidium-82 half-life	Requires local or regional operational capability
PET infrastructure	Restricts use to equipped imaging centers
Radiation licensing	Adds site-level compliance requirements
Clinical workflow	Requires trained staff and rapid imaging
Reimbursement	Determines whether centers adopt cardiac PET

A competitor can face meaningful entry barriers even after basic patent rights expire. Manufacturing know-how, radionuclide supply agreements, validated generator designs, and customer service infrastructure can have greater practical importance than a single formulation patent.

Which companies are challenging or competing with RUBY-FILL?

The principal competitive threat is not a conventional generic manufacturer. It comes from alternative cardiac PET approaches and competing generator or isotope platforms.

Relevant competitive categories include:

• Other rubidium-82 generator systems.
• Nitrogen-13 ammonia PET, where local cyclotron capacity exists.
• Fluorine-18 myocardial perfusion agents.
• SPECT myocardial perfusion imaging using technetium-99m or thallium-201.
• Stress echocardiography and stress magnetic resonance imaging.
• New PET perfusion agents with longer distribution windows.

Jubilant’s commercial position benefits from the operational simplicity of rubidium-82 compared with short-lived cyclotron-produced tracers. That advantage is offset by generator cost, limited isotope supply, and the need for specialized PET infrastructure.

What patent litigation affects RUBY-FILL?

No widely reported patent litigation is identified in the cited FDA materials as a direct determinant of RUBY-FILL market access. The most important legal risks are likely to involve generator architecture, isotope production, sterile delivery systems, and manufacturing processes rather than the sodium chloride carrier.

Potential dispute areas include:

• Strontium-82 generator column construction.
• Adsorbent materials and radionuclide separation.
• Elution and breakthrough-control methods.
• Automated dose delivery systems.
• Disposable tubing and fluid-path assemblies.
• Radiation-shielding and generator-monitoring systems.
• Process controls for commercial-scale isotope manufacture.

A competing company could avoid a formulation claim by using the same saline carrier while still infringing claims directed to generator structure or isotope separation. Conversely, a narrow generator patent may have limited practical value if alternative column materials or operating parameters are available.

How strong is the RUBY-FILL patent estate?

The commercially relevant IP estate is likely stronger around manufacturing and system integration than around excipients. Patent strength should be assessed across four layers:

IP layer	Expected commercial relevance
Generator architecture	High
Radionuclide production and separation	High
Sterile delivery and automation	Moderate to high
Saline-based formulation	Low to moderate

Manufacturing patents can be difficult to design around when they cover validated control of strontium breakthrough, generator lifetime, and reproducible elution. Their value increases when few isotope suppliers exist. Formulation claims limited to rubidium-82 in saline would likely provide narrower protection because the carrier is simple and technically familiar.

Trade secrets can be important. These may cover resin preparation, column loading, sterilization, quality-control thresholds, production yields, and isotope-handling procedures. Unlike patents, trade secrets do not provide a public expiration date but depend on continued confidentiality and operational control.

What commercial opportunities exist in RUBY-FILL excipients and accessories?

The strongest opportunities are adjacent to the excipient rather than in the excipient itself.

Validated saline and sterile fluid kits

A supplier could market a generator-compatible sterile saline package with validated containers, connectors, tubing, and storage conditions. The commercial advantage would come from regulatory documentation and workflow compatibility, not from a novel saline composition.

Closed-system delivery components

Low-volume, low-sorption tubing and connectors can reduce dose loss and contamination risk. A preassembled closed system could simplify installation and reduce operator error.

Automated dose management

Software that links the generator, dose calibrator, infusion pump, PET scanner, and patient record could improve scheduling and dose documentation. This is a higher-value opportunity than an incremental excipient change.

Quality-control products

Rapid tests for radionuclide identity, strontium breakthrough, radiochemical purity, and dose accuracy can support hospital and radiopharmacy operations. Products that reduce release time have direct commercial value because rubidium-82 decays rapidly.

Generator services

Maintenance, calibration, replacement logistics, radiation-safety support, and staff training can produce recurring revenue. These services also increase customer retention.

PET center expansion

RUBY-FILL adoption can support cardiac PET growth at hospitals that already own PET/CT systems but do not have a cyclotron. The opportunity is strongest where cardiac PET reimbursement, cardiology referral volume, and radiopharmacy logistics are favorable.

How does RUBY-FILL compare with longer-lived PET radiopharmaceuticals?

Attribute	RUBY-FILL/Rb-82	F-18 perfusion agents	SPECT tracers
Production model	Generator	Cyclotron and radiopharmacy	Reactor or generator supply chain
Half-life	About 75 seconds	Longer, often allowing distribution	Longer than Rb-82
On-site cyclotron	Not required	May be required or regional	Not required
Imaging workflow	Immediate administration	More scheduling flexibility	Broad installed base
Formulation complexity	Low	Agent-dependent	Agent-dependent
Supply risk	Strontium-82 and generator availability	Isotope production and distribution	Isotope availability
Main commercial barrier	Generator cost and PET access	Manufacturing and distribution	Lower equipment cost but lower PET resolution

RUBY-FILL has a strong fit for centers seeking cardiac PET without building a cyclotron. Longer-lived fluorine-18 products may have better distribution economics and scheduling flexibility, while SPECT remains more accessible because of installed equipment and lower capital requirements.

What generic launch scenarios exist for RUBY-FILL?

Three entry scenarios are commercially plausible:

1. Competing generator approval. A manufacturer launches a functionally comparable strontium-82/rubidium-82 generator.
2. Alternative PET tracer substitution. A longer-lived myocardial perfusion tracer captures centers seeking easier scheduling and distribution.
3. Platform unbundling. Third-party companies supply validated fluid sets, automation, QC, and service products around existing generators.

The first scenario requires the greatest capital and regulatory investment. The third can be pursued with lower development risk but may face supplier qualification, device regulation, and contractual barriers.

What is the revenue exposure to RUBY-FILL?

Revenue exposure depends on generator placements, active PET sites, renewal frequency, generator service revenue, isotope costs, and reimbursement for myocardial perfusion PET. The short half-life creates recurring operational demand but also makes the product dependent on high-throughput imaging centers.

The largest business risks are:

• Strontium-82 supply interruption.
• Generator manufacturing delays.
• Limited cardiac PET reimbursement.
• Competition from fluorine-18 PET agents.
• Hospital capital constraints.
• Radiation-safety and radiopharmacy staffing shortages.
• Low utilization at centers with insufficient cardiac volume.

The largest upside is expansion of cardiac PET in hospitals that lack cyclotrons but have PET/CT capacity and cardiology referral networks.

Key Takeaways

• RUBY-FILL is a strontium-82/rubidium-82 generator, not a conventional finished-dose pharmaceutical.
• The administered product uses sterile 0.9% sodium chloride as the principal carrier.
• Excipient innovation has limited value because the dose is generated immediately before administration and decays rapidly.
• The stronger commercial opportunities are validated saline kits, sterile fluid paths, automation, QC systems, and generator services.
• Patent value is likely concentrated in generator architecture, radionuclide separation, manufacturing, and delivery systems.
• Generic substitution is not the primary near-term threat. Competing generators, fluorine-18 PET agents, and SPECT remain the relevant alternatives.
• Strontium-82 supply, generator manufacturing, reimbursement, and PET infrastructure are central to market access and revenue durability.

FAQs About RUBY-FILL Excipient and Commercial Strategy

Does RUBY-FILL contain preservatives?

Public product information identifies sterile 0.9% sodium chloride injection as the principal carrier and does not identify a preservative as a functional component of the administered product [1].

Can another saline solution be used with RUBY-FILL?

Only a fluid that meets the approved product specifications and validated generator operating requirements should be used. Carrier substitution can affect sterility, elution performance, radionuclide purity, and dose accuracy.

Is RUBY-FILL a biologic or biosimilar product?

No. RUBY-FILL is a radiopharmaceutical generator. Biosimilar rules do not apply to its market-entry model.

What is the largest manufacturing barrier for a RUBY-FILL competitor?

The principal barriers are reliable strontium-82 supply, generator-column manufacturing, radionuclide purity control, sterile assembly, and validated control of strontium breakthrough.

Can an excipient patent block a RUBY-FILL competitor?

A narrow patent covering rubidium-82 in saline would likely provide limited competitive protection by itself. A broader patent covering the generator, elution process, fluid pathway, or quality-control method could create a more significant barrier.

References

1. U.S. Food and Drug Administration. (n.d.). RUBY-FILL (strontium Sr-82/rubidium Rb-82 generator) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2016). RUBY-FILL approval letter and application materials. FDA, Center for Drug Evaluation and Research.

3. National Library of Medicine. (n.d.). DailyMed: RUBY-FILL strontium Sr-82/rubidium Rb-82 generator. U.S. National Library of Medicine.

4. Jubilant Radiopharma. (n.d.). RUBY-FILL rubidium Rb-82 generator product information. Jubilant Radiopharma.